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Adrenal masses are among the most prevalent human tumors and are frequently detected unexpectedly by an 
imaging study performed for reasons unrelated to suspect of adrenal diseases.  The widespread use of 
computed tomography (CT), diagnostic ultrasound (US), and magnetic resonance imaging (MRI) has 
resulted in the frequent incidental discovery of asymptomatic adrenal masses. Such masses are commonly 
defined as adrenal incidentalomas and represent a public health challenge because they are increasingly 
recognized in current medical practice (1). Adrenal incidentalomas raise challenging questions for both 
physicians and their patients and represent one of the leading reasons for seeking endocrinological 
consultation. On the basis of these considerations, the Italian Association of Clinical Endocrinologists 
(AME) thought it timely and appropriate to appoint a panel of Italian experts in the field of adrenal diseases 
with the task to write a Position Statement whose intent was to assess and synthesize currently available data 
regarding adrenal incidentaloma and provide recommendations for clinical practice. 
  
 
METHODOLOGY 
Adrenal incidentaloma is not a single entity; rather, it is an „umbrella‟ definition comprising a spectrum of different 
pathological entities that share the same path of discovery. The likelihood of any specific condition depends greatly on 
the definition of incidentaloma and the circumstances of discovery. Unfortunately, published reports are inconsistent in 
applying definite inclusion and exclusion criteria, making their results difficult to interpret. Including patients with 
signs and symptoms attributable to an adrenal tumor will increase the proportion of large masses or biochemically 
active tumors. Conversely, studies that exclude patients with signs or symptoms will find a greater proportion of small 
masses and biochemically silent tumors. Since the definition of incidentaloma was heterogeneous across the studies, the 
panel accepted all studies independent of their respective definitions of incidentaloma, rather than choosing a narrow 
definition that may exclude potentially relevant studies. 
The panel searched for and summarized evidence on several key questions on adrenal incidentalomas that were 
formulated by the panel prior evaluating the literature with the aim to provide recommendations for clinical practice 
(Table 1). A comprehensive search of the medical literature was then conducted to identify relevant studies that were 
identified primarily through a MEDLINE® search of the English language literature published between 1966 and 2009. 
References of selected review articles were also examined to identify additional studies and other reports that were 
considered relevant by the panel. The panel appraised the methodological quality of the studies that met the inclusion 
criteria, summarized their results and discussed the evidence reports to find consensus. The Position Statement was 
reviewed by a group of distinguished international experts and the panel incorporated needed changes in response to 
their written comments. 
The methodology of the present Position Statement is based upon the Grading of Recommendations, Assessment, 
Development and Evaluation (GRADE) system (2-4). The GRADE system requires that the quality of evidence is 
integrated with other factors, so that the strength of recommendations is not necessarily, although  in most cases is, 
related to the levels of evidence. The panel used “recommend” for strong recommendations, and “suggest” for weak 
recommendations. 
  
EPIDEMIOLOGY 
 
QUESTIONS 
1. What is the frequency of an incidental adrenal mass in the population? 
Available information is scanty and extrapolated from either clinical or autopsy series. Most experts agree on 
considering as incidentalomas adrenal masses of 10 mm, or more, in size although different criteria were used to define 
a discrete adrenal mass (5-8). In autopsy series, the mean prevalence of clinically inapparent adrenal masses is about 
2.0%, ranging from 1.0 to 8.7% (5-7). Prevalence increases with age with no difference in sex (5-10) and is higher in 
white than black people (4, 10) and also in obese, diabetic and hypertensive patients (7).   
In clinical series, prevalence figures have most likely underestimated the actual frequency of adrenal incidentalomas 
because most data were generated with radiological equipment now considered obsolete, as imaging technology has 
improved considerably in recent years. In radiological studies, the frequency of adrenal incidentalomas was estimated at 
approximately 4% in middle age and increases up to more than 10% in the elderly, peaking around the fifth and seventh 
decade (7-11). Adrenal incidentalomas are slightly more frequent in women as a result of a referral bias (9, 10). The 
frequency of adrenal incidentalomas is very low in childhood and adolescence accounting for 0.3-0.4% of all tumors in 
children (12).  
 
2. What are the causes of an incidental adrenal mass in the population? 
Etiology includes either benign or malignant lesions. There is consistent evidence that most adrenal incidentalomas are 
benign adrenal adenomas, that account for approximately 80% of all tumors, even if a precise estimate is impossible 
because adrenal adenomas are rarely excised (5-11, 13-15). The frequency of pheochromocytoma ranges between 1.5-
23%, whereas adrenocortical cancer (ACC) varies from 1.2% to 12% (5-7, 9, 15) among different studies. Such a great 
variability in the reported frequency of pheochromocytoma, ACC and other histological diagnoses depends on the 
inclusion criteria and referral pattern of the various studies. Accordingly, the most frequent tumor types as they are 
reported in clinical and surgical studies are reported in Table 2a and 2b, respectively.  
A recent review of the literature concluded that the prevalence of malignant and functional lesions is likely to have been 
overestimated in the literature (16). The figures reported in most papers are likely to be biased by preferential inclusion 
of surgical patients and patients with a history of malignancy. In their review, Cawood et al. (16) estimated a frequency 
around 2.0% for ACC, less than 1.0% for adrenal metastases and around 3.0% for pheochromocytoma. These figures 
are lower than those generally reported in reviews that did not use a narrow definition of adrenal incidentaloma, but 
accepted all studies with their own definition. In such highly referenced reviews, prevalence of ACC was reported in the 
range of 4.0-5.0%, pheochromocytoma 5.0-6.0% and metastasis 2.0%, respectively (5, 10, 17). Cysts, ganglioneuromas, 
myelolipomas, hematomas and metastases from extra-adrenal cancers represent other possible causes of adrenal 
incidentalomas (5, 7, 9, 18). The adrenal glands are frequently affected by metastatic spreading of a variety of primary 
cancers (lung cancer, breast cancer, kidney cancer, melanoma and lymphoma) and in cohorts of oncological patients, 
50-75% of adrenal incidentalomas are metastases (8, 19-21). An adrenal incidentaloma may represent a metastasis from 
an unknown extra-adrenal malignancy; this presentation of an advanced malignancy is unusual and was found to occur 
in 5.8% of over 1600 patients with various types of carcinoma when both the adrenal glands were affected, but only in 
0.2% when adrenal involvement was monolateral (22). However, ACC represents 1.3% of all malignancies in patients 
<20 years and ACC frequency peaks at <4 years (23).  
  
Up to 15% of patients with adrenal incidentaloma have bilateral adrenal masses and the most likely diagnoses are 
metastatic or infiltrative diseases of the adrenal glands, congenital adrenal hyperplasia, bilateral cortical adenomas and 
ACTH-independent macronodular adrenal hyperplasia (AIMAH) (24). 
The prevalence results derived by combining data from reported series should be interpreted with caution. The lack of a 
uniform definition of incidentaloma (and the consequent heterogeneity of inclusion and exclusion criteria), the selective 
sampling of patients and reporting of information, and the retrospective nature of most of the studies may result in 
biased estimations of the prevalence of various pathologies. The underlying distribution of adrenal pathology in 
incidentaloma is influenced by a number of factors that were not consistently controlled for in many of the studies. The 
limitations of epidemiological data due to inherent bias of the literature, and the paucity of studies done in the general 
healthy population, allow a few recommendations for clinical practice. Recommendations for clinical practice based on 
epidemiology of adrenal incidentalomas are given in Table 3.  
 
 
  
RADIOLOGICAL ASSESSMENT  
 
QUESTIONS 
 
1. What is the diagnostic accuracy of the imaging modalities used to differentiate the various types of adrenal 
incidentalomas? 
 
A common limitation of the available studies is the use of broad inclusion criteria which included not only adrenal 
incidentalomas but also clinically overt adrenal masses. Moreover, ascertainment of outcome with a definitive 
pathological diagnosis was missing in most cases. With few exceptions (25), the final diagnosis was most frequently 
inferred from stability of the adrenal mass over variable periods of observation (at least 6 months). Another common 
limitation is the lack of a clear definition of the test accuracy that, therefore had to be inferred indirectly. In general, 
sensitivity refers to the percentage of subjects with an adrenal malignancy (either ACC or metastasis) with a positive 
test, and specificity refers to the percentage of subjects without an adrenal malignancy with a negative test. However, a 
clear differentiation between ACC and metastases has been inconsistently pursued. Pertinently, relatively few patients 
with ACC compared to adrenal metastases have been included in the radiological studies that are mostly retrospective. 
 
Ultrasonography  (US) 
The utility of US depends to a large extent on operator skill. Obesity and overlying gas are frequent 
obstacles for visualization of the adrenal glands (26). Thus, US does not detect adrenal masses with 
the same sensitivity as CT or MRI (27, 28). According to one study (29), the sensitivity in detecting 
incidentalomas depends on the mass size, being 65% for lesions <3 cm and 100% for lesions >3 
cm. Another study found that US has a good reliability in evaluating mass size and its growth with 
time, but has no role in differentiating between benign and malignant adrenal masses (30). 
 
Unenhanced Computed Tomography   
A key point is that most abdominal and chest CT scans leading to the unexpected discovery of an adrenal mass are now 
obtained with the use of intravenous contrast and may not fulfill current technical recommendations for an optimal CT 
study of the adrenal glands, including analysis on contiguous 3-to-5-mm thick CT slices, preferentially on multiple 
sections using multidetector row protocols (31). In that cases, it may be worthwhile to obtain an unenhanced CT scan 
specifically aimed to the study of the adrenal glands (14). 
Both CT and MR are lipid-sensitive imaging tests that exploit the fact that up to 70% of adrenal adenomas contain 
abundant intracellular fat whereas almost all malignant lesions do not (5-7). There is an inverse linear relationship 
between fat concentration and attenuation on unenhanced CT images. Thus, the CT densitometry technique shows that 
the mean attenuation value of adenomas is significantly lower than that of non-adenomas. CT densitometry is key since 
the structural features of most adrenal masses are not specific enough to allow a precise characterization. The size and 
appearance of an adrenal mass on CT may help distinguishing between benign and malignant 
lesions. In previous studies, a cut-off of 4 cm in size has been reported to be the most reliable way to diagnose 
malignancy (or non-adenomatous lesions) but with a very low specificity (5, 9, 17). More recent studies found that CT 
attenuation value, expressed in Hounsfield units (HU), is a superior parameter but can also be used in a 
composite criteria (25). Six studies (730 patients) showed that a density of ≤10 HU had the best accuracy with a 
sensitivity of 96% - 100% and a specificity of 50% - 100% in differentiating benign to malignant masses (25, 32-35-
  
36). Lesions with a density >10 HU on unenhanced CT are considered indeterminate and other tests are generally 
required for characterization, since 30% of adrenal adenomas are lipid-poor tumors that may show attenuation values > 
10 HU (32-35, , 36,). A single study suggested that all non-calcified, non-hemorrhagic adrenal lesions with attenuation 
values of > 43 HU should be considered suspicious for malignancy (31). 
 
Enhanced Computed Tomography  
The percentage washout on delayed images contributes to the differentiation between adenomas and malignant adrenal 
masses because enhancement – i.e. “washout” – decreases more quickly in adenomas than malignant masses: a 10-15 
minute delay after administration of contrast medium was accepted by most authors (31-36). There are two methods to 
measure percentage washout: absolute percentage washout (APW) and relative percentage washout (RPW). Blake et al 
(31) provided the following formulas: 
 APW = 100 x (EA – DA) / (EA – PA) 
 RPW = 100 x (EA – DA) /  EA 
where EA is attenuation on contrast-enhanced scans (60 – 70 seconds after administration of contrast medium), DA is 
attenuation on delayed contrast-enhanced scans (protocol with 10 minute delay), and PA is pre-contrast  attenuation. All 
attenuation measurements are in Hounsfield units. 
Lipid-poor adenomas represent 10%-40% of adenomas and typically demonstrate rapid washout with an absolute 
washout of more than 60% (sensitivity  of 86 – 100%, specificity of 83 – 92%) and a relative washout of more than 
40% (sensitivity of 82 – 97%), specificity of 92 – 100%) on delayed images (35). After contrast medium administration 
metastases usually demonstrate slower washout on delayed images (APW <60%, RPW <40%) than adenomas. ACC 
typically has a RPW of less than 40%, however, large size and heterogeneity are more reliable indicators of malignancy 
than are washout values (36 bis). ROC analysis of the performance of APW and RPW criteria in enabling 
differentiation between benign and malignant adrenal masses (excluding pheochromocytomas, cysts and myelolipomas 
from analysis) showed that APW criteria were more discriminating than RPW criteria (31). The APW allows a more 
accurate calculation of the mass enhancement, because the pre-contrast attenuation value is included in the formula, 
thus resulting in a more accurate characterization of the washout.  
However,  all the studies had limitations due to the retrospective analysis of data and the fact that the nature of most 
adrenals masses was not pathologically proved but was often assumed by imaging follow-up, so that stable dimensions 
over a given period were considered as  demonstrating a benign nature (35). In one study, enhanced CT was done as a 
second-line procedure when mass density was >10 HU on unenhanced CT and that enabled a better differentiation of 
adenomas from non-adenomas (34). Delayed contrast-enhanced CT is emerging as an extremely accurate imaging test 
to differentiate adrenal lesions, although there is some debate as to the percent washout threshold allowing the most 
accurate differentiation of adenomas from non-adenomas. Furthermore, there is some heterogeneity in the data on 
sensitivity and specificity of this technique across different studies.  
 
Magnetic Resonance Imaging  
Magnetic resonance imaging is as effective as CT in distinguishing benign from malignant lesions. The 
differentiation between benign and malignant masses was based more on findings from chemical 
shift studies than on the signal intensities of conventional techniques. Chemical-shift imaging relies 
on the different resonance frequencies of protons in water and triglyceride molecules and therefore 
may permit a more specific diagnosis of adrenal adenomas, known to contain abundant lipids. The 
  
studies reported quantitative or qualitative analysis of signal intensity loss in the adrenal lesions 
relative to reference tissues (liver, muscle, and spleen) on in-phase and opposed-phase sequences as 
means to differentiate adenomas from non-adenomas. The loss of signal on out-of-phase images in relation 
to spleen (to avoid the confounding of liver steatosis) differentiated adenomas from non-adenomas with a sensitivity of 
84% - 100%  and a specificity of 92% - 100% (37-40). In general, adenomas appear as hypo- or iso-intense 
in comparison to the liver on T1-weighted images and hyper- or iso-intense to the liver on T2-
weighted images. A study proposed the criterion of hyperintensity on T2-weighted images (without setting a 
threshold) to differentiate benign from malignant masses (41). 
Considering that chemical shift MR and unenhanced CT densitometry tests are both based on detection of intracellular 
lipid, there has been a debate as to which test might be superior. Studies have shown that for lipid-rich adenomas there 
is no apparent difference between the tests, but chemical shift imaging might be superior when evaluating lipid-poor 
adenomas with an attenuation value up to 30 HU (42, 43). We do not have enough evidence on the comparison between 
CT and MR, however, in the everyday practice CT plays a primary role for the radiological assessment of adrenal 
incidentalomas. Thus, other imaging tests (including MR and PET) should only be employed in unusual circumstances 
(44-47). 
 
Scintigraphy      
Two radiocholesterol derivatives have been mainly studied: 
131
I-6--iodomethyl-norcholesterol 
(NP-59) and 
75
Se-selenomethyl-19-norcholesterol for morphological and functional imaging of 
adrenal cortex (48). A disadvantage with the radiotracers is their inherent high radiation dose (49). 
A concordant scintigraphic pattern, defined as a unilateral adrenal visualization, or increased 
radiotracer uptake at the side of the detected mass, has been proposed as a typical pattern of benign 
cortical adenoma or nodular hyperplasia. In contrast, a discordant pattern with absent, decreased, or 
distorted uptake by the adrenal mass may indicate ACC, metastasis, or other nonfunctioning, space-
occupying or destructive adrenal lesions. Two studies found that sensitivity ranged from 71 to 100% and 
specificity from 50% to 100% for differentiating benign from malignant lesions (50, 51) Due to the limited resolution of 
scintigraphy, concordant and discordant patterns of uptake may not be demonstrable in lesions less than 2.0 cm in 
diameter (51, 52). It has also to be considered that some benign adrenal tumors of extra-cortical origin, i.e. 
myelolipoma, do produce a discordant pattern of uptake (suggestive of a malignancy) and well-differentiated ACC may 
show uptake of the tracer. These exceptional ACCs are usually associated with overt Cushing‟s syndrome or 
mineralocorticoid excess  (53).  
NP-59 adrenal scintigraphy was also extensively used to assess functional autonomy of adrenal incidentalomas 
(adenomas) and to differentiate functioning from non-functioning tumors (10, 50, 53). Some adrenal adenomas can 
produce an amount of cortisol sufficient to reduce ACTH secretion, and suppress the uptake of the contralateral gland 
as well, but not enough to cause clinically overt signs, in analogy with hot, pre-toxic, thyroid nodules (5-7, 10, 51).  NP-
59 uptake on the side of the mass with non-visualization of the contra-lateral adrenal gland (concordant uptake) may 
occur despite overall normal endocrine tests (13). Scintigraphic uptake thus represents a very precocious sign of 
functional autonomy, but the low specificity of this finding makes it of doubtful clinical utility.  
  
Overall, insufficient spatial resolution, lack of widespread expertise, limited availability of the tracer, and length of the 
procedure, which  requires serial scanning over a 5- to 7-day span, are the main inconveniences of adrenal scintigraphy 
(52).  
 
PET scan 
The concept of 
18
F-FDG PET is based on an increased glucose uptake by malignant lesions. The 
quantitative analysis of FDG uptake is performed using standardized uptake values (SUV) or by 
qualitative visual evaluation with respect to liver uptake. The sensitivity of FDG-PET in identifying 
malignant lesions varied between 93% - 100% with a specificity between 80% - 100% (54-58). 
Necrotic or hemorrhagic malignant adrenal lesions may cause false-negative results showing poor 
FDG uptake. PET imaging is not reliable for lesions <1 cm in size, as metastatic lesions of this size 
may demonstrate less radiotracer uptake than normal liver.   
Recent studies demonstrated that a maximal SUV ratio (adrenal to liver maximal standardized 
uptake value activity) less than 1.45 - 1.60 is highly predictive of a benign lesion (59-63). The use of 
PET/CT may offer advantages over PET alone as the morphology of the lesion can be assessed by CT while its 
metabolic activity is measured concomitantly by PET, allowing for accurate anatomic localization of any FDG focal 
uptake. CT densitometry and washout measurements (if a delayed contrast-enhanced CT is performed) can be 
incorporated into the analysis. The sensitivity of PET-CT ranged between 98.5% – 100% and specificity 
between 92% - 93.8% (60-63). The addition of wash-out measurements on contrast-enhanced CT in 
one study increased specificity to 100% (64).  
 
18
F-FDG PET or PET/CT may be a useful tool  for distinguishing potentially malignant lesions 
from benign tumors in radiologically indeterminate adrenal lesions; thus, patients who have an 
adrenal lesion with inconclusive CT densitometry or washout analysis should be referred for 
characterization with 
18
F-FDG PET (44, 59). Sensitivity of 18F-FDG PET imaging is only 
moderate, however, for the diagnosis of small lesions and also false positive results have to be 
considered (i.e. some adrenal adenomas and pheochromocytomas may uptake FDG). Because of its 
excellent negative predictive value, 18F-FDG-PET may be of help in avoiding unnecessary surgery 
in patients with non-secreting equivocal tumors at CT scanning and low 18F-FGD uptake. 
Moreover, 
18
F-FDG PET may favor surgical removal in tumors with elevated uptake and no 
biochemical evidence of pheochromocytoma (60).  
For differentiation between lesions of adrenocortical or non-adrenocortical origin metomidate, 
which specifically binds to adrenal CYP11B enzymes, has been introduced as a PET tracer (11C-
Metomidate PET) (65, 66). Translation into clinical practice of 11C-Metomidate PET is hampered 
by the need of on-site cyclotrons, justifying introduction of the SPECT tracer 123I-Iodometomidate. 
Preliminary data show that his new tracer specifically accumulates in adrenocortical tissue with 
excellent visualization of benign adrenal tumors; however, tracer uptake in patients with ACC is 
  
heterogeneous and may be affected by treatment (67). Metomidate based tracers hold promise to 
refine our ability to characterize functionally adrenal tumors, but are not yet widely available. 
 
Fine needle aspiration biopsy (FNAB)    
Studies reported a sensitivity of 81% - 96% and a specificity of 99% - 100% to identify malignant masses. Inconclusive 
biopsies were reported in 6% - 50% of samples (68-70). Complications of FNAB have not been adequately reported in 
all studies; however, the rate of adverse events is ranging from 2.8% to 14%. No reliable estimates can be made about 
the relative safety of the different biopsy techniques; however, performing FNAB carries a small but definitive risk of 
morbidity and mortality from pneumothorax, bleeding, infection and pancreatitis (7, 71). Moreover, biopsy of an ACC 
may result in needle track seeding of tumor cells (17, 72). The necessity for FNAB has been reduced by the accuracy of 
contemporary adrenal imaging techniques designed to characterize adrenal disease (72, 72bis).   
FNAB is not accurate in differentiating benign from malignant primary adrenal tumors and may be useful in selected 
cases only, in patients with history of an underlying extra-adrenal malignancy and inconclusive results of imaging tests, 
or if there is suspicion of a rare tumor (47, 72bis). It is mandatory to exclude biochemically a pheochromocytoma 
before FNAB is performed (73). Recommendations on the radiological assessment of adrenal incidentalomas are given 
in Table 4. 
 
 
 
 
 
 
 
 
 
 
 
  
 HORMONAL EVALUATION 
 
All subjects with an incidentally discovered adrenal mass should be screened for both catecholamine excess and 
hypercortisolism, with the exception of patients with adrenal masses whose imaging characteristics are typical for 
myelolipoma or adrenal cyst. Primary hyperaldosteronism should be considered in hypertensive and/or hypokalemic 
patients. Using the strictest inclusion criteria and the purest definition of incidentaloma, which imply the lack of the 
more specific signs of hypercortisolism, will reduce the proportion of secretory tumors and will virtually eliminate the 
possibility of overt Cushing (6, 14, 17). However, physicians who are not familiar with Cushing‟s syndrome might 
overlook (mild) signs of hypercortisolism and will pursue evaluation of adrenal function only following the (incidental) 
discovery of an adrenal mass. 
 
QUESTIONS 
1. What is the diagnostic accuracy of the various biochemical tests used to detect secretory 
activity of adrenal incidentalomas?  
 
Screening of pheochromocytoma 
Screening for pheochromocytoma should be done also in normotensive patients and even if the imaging characteristics 
of the tumor are not suggestive for a catecholamine-producing tumor (6, 14, 17). In all patients with adrenal 
incidentalomas, fractionated metanephrines should be measured in urine (sensitivity 97%) or free metanephrines in 
plasma (sensitivity 99%) (74, 75). Normal results rule out pheocromocytoma while an elevation of more than fourfold 
above the reference interval establishes the diagnosis (76). False positive results should be considered in patients with 
equivocal elevation of plasma, or urinary normetanephrine. In these subjects, measurements should be repeated in the 
absence of possible interfering conditions (76-78). A thorough discussion of the diagnostic approach to 
pheochromocytoma is beyond the scope of this Position Statement and the reader is referred to recent comprehensive 
reviews (77, 78). 
 
Screening of primary aldosteronism 
According to the Endocrine Society‟s Clinical Guidelines for Management of Primary 
Aldosteronism and the AACE/AAES Medical Guidelines for the Management of Adrenal 
Incidentalomas, all patients with an incidentally discovered adrenal mass and hypertension should 
be tested for hyperaldosteronism (79, 80). The recent demonstration that primary aldosteronism 
sustained by an adrenal adenoma may cause hypokalemia without hypertension (81) supports the 
measurement of plasma aldosterone and plasma renin activity (PRA), or direct renin concentration, 
in all hypertensive or hypokalemic patients. The evaluation should be performed paired at mid 
morning on outpatient basis after correction of hypokalemia, if present; dietary salt intake must be 
unrestricted (80, 82). Spironolactone must be discontinued at least for 6 weeks. Angiotensin 
converting enzyme inhibitors, angiotensin receptor blockers, dihydropyridine calcium channel 
antagonists, beta-blockers, central alpha-2 antagonists (clonidine), non steroidal anti-inflammatory 
drugs, potassium-wasting diuretics, amiloride, licorice and chewing tobacco must be discontinued 
  
at least for 4 weeks. Hypertension can be controlled with non-interfering medication, such as 
verapamil and/or doxazosin (79). The plasma aldosterone/renin ratio (ARR) should be calculated. 
Although discrepant data of the literature preclude definition of a certain threshold, primary 
aldosteronism should be suspected in the presence of ARR >30-50 (plasma aldosterone is expressed 
as ng/dL and PRA as ng/ml/h) (79, 83-86) or 3.7 (plasma aldosterone as ng/dL and direct renin 
concentration as ng/L) (87, 88). A thorough discussion of the diagnostic approach to primary 
aldosteronism is beyond the scope of this Position Statement and the reader is referred to the recent 
Endocrine Society‟s Clinical Guidelines (79).  
 
Screening of overt Cushing‟s syndrome 
According to the Endocrine Society‟s Clinical Guidelines for the diagnosis of Cushing‟s syndrome 
and the AACE/AAES Medical Guidelines for the Management of Adrenal Incidentalomas, all 
patients with an incidentally discovered adrenal mass should be tested for hypercortisolism (89). 
Overt cortisol excess should be suspected in the presence of one out the following four symptoms 
that are relatively specific for endogenous hypercortisolism: 1) easy bruising, 2) facial plethora, 3) 
proximal myopathy or muscle weakness, 4) reddish-purple striae >1 cm wide (88). As 24-h UFC is 
relatively insensitive for detection of mild hypercortisolism (13), the 1 mg overnight 
dexamethasone suppression test (1-mg DST) should be used for screening (6, 14, 17). Setting the 
threshold at 1.8 g/dL, 95% sensitivity is achieved (90-92) but the physician should be aware of 
conditions potentially leading to false positive, and less frequently or false negative, results (93-95). 
A thorough discussion of the diagnostic approach to overt Cushing‟s syndrome is beyond the scope 
of this Position Statement and the reader is referred to the recent Endocrine Society‟s Clinical 
Guidelines (89).  
 
Evaluation of subclinical Cushing‟s syndrome  
We specifically searched for articles including biochemical tests to screen for subclinical Cushing‟s 
syndrome in patients with adrenal incidentaloma. We decided to select only studies with a caseload 
of at least 20 subjects with incidentally discovered adrenal adenomas. We have excluded the studies 
without either clearly defined criteria to qualify for subclinical Cushing‟s syndrome or clear 
reporting of the frequency of the abnormalities of the HPA axis. However, only few studies have 
reported the sensitivity and specificity of the considered tests (dexamethasone suppression test, late 
night serum or salivary cortisol, urinary free cortisol, and ACTH) and inclusion criteria were 
heterogeneous across the studies (Table 5).   
Subclinical Cushing‟s syndrome is the most frequent endocrine dysfunction detected in patients 
with adrenal incidentalomas, accounting from 5% to 20% of all cases. This variability depends on 
  
inclusion criteria, study design, work-up protocols and mainly diagnostic criteria of subclinical 
Cushing‟s syndrome (14, 96). A major challenge is that Cushing‟s syndrome includes a spectrum of 
clinical presentations that is difficult to sort out in different categories. The heterogeneity of the 
clinical phenotype depends mainly on the variability of cortisol secretion that is distributed 
continuously from apparently non-functioning adrenal adenomas to overtly cortisol-producing 
adenomas. Categorization of Cushing‟s syndrome is also influenced by clinical experience, since 
physicians who have less expertise might overlook (mild) signs of hypercortisolism. For these 
reasons, demonstration of subclinical Cushing‟s syndrome is extremely difficult in practice. The 
standard biochemical tests used to screen for overt Cushing‟s syndrome are generally ill suited for 
the assessment of patients who have no sign of cortisol excess, or only non-specific features, such 
as centripetal obesity, when patients with “true” adrenal incidentalomas are selected. In this clinical 
setting, the a priori probability of subclinical Cushing‟s syndrome may be roughly comparable with 
the false-positive rate of the tests used for screening. Thus, it remains to be defined what strategy is 
best suited to detect subclinical Cushing‟s syndrome, or silent cortisol excess (96-98).  
The DST has been widely employed to unmask subtle abnormalities of cortisol secretion in patients with adrenal 
incidentalomas and most authors use the overnight 1 mg DST, which is easy to perform in clinical practice (9, 13, 99-
123). Sensitivity and specificity for the 1 mg DST have been reported in four papers (9, 115, 116, 118), whereas only 
one of them has described the diagnostic accuracy of UFC, ACTH or late night serum cortisol (9). Available data 
suggest that the 1 mg DST should be the first screening test; however, there is no consensus on the test modality (single 
dose versus 2-day administration). Moreover, a debate continues also on the cut-off values to consider the test as 
positive. To provide a standard, in 2002 the NIH state-of-the-science conference panel recommended the 1-mg DST 
with the traditional threshold of 5 g/dL (138 nmol/L) to define adequate suppression (6). Lower cut-off values have 
been advocated to increase detection of subclinical Cushing‟s syndrome following the recommendations for screening 
of overt Cushing‟s syndrome (105, 107, 112, 113, 115, 116, 122). However, specificity is an issue when post-
dexamethasone cortisol thresholds as low as 1.8 g/dl (50 nmol/l) are used, which may result in more false positive 
results (115, 116). A recent addition to this controversy comes from the French Society of Endocrinology who 
recommended a cutoff for the 1-mg DST at 1.8 g/dl (50 nmol/l) in the screening for subclinical Cushing‟s syndrome 
(124). Conversely, according to the AACE/AAES Medical Guidelines for the Management of Adrenal Incidentalomas, 
diagnosis of subclinical Cushing‟s syndrome is made if the serum cortisol level is > 5.0 g/dl after a 1-mg DST (80).  
Other authors have suggested the standard 2-day low-dose DST or high-dose (3 mg or even 8 mg) DST (99, 100, -108-
110,  112, 120, 121, 122). The 2-day low-dose DST is more cumbersome to perform, therefore it may be considered as 
a confirmatory procedure or in the context of psychiatric diseases, alcoholism and diabetes mellitus, where it may have 
greater accuracy (89, 109). Up to now, there is no direct head-to-head comparison of the different DSTs, or different 
thresholds after the 1-mg DST, to establish a gold standard for diagnosing SCS. However, in a recent study the results 
of the overnight 1-mg DST and 8-mg DST were compared in 22 out of 68 patients who did not suppress cortisol below 
1.8 g/dl (50 nmol/L). The results of the 8-mg DST did not change the probability to have subclinical Cushing‟s 
syndrome defined by the 1-mg DST (125).  
Evaluation of other possible markers of adrenal autonomy, such as 24h UFC excretion, midnight serum cortisol, plasma 
ACTH, or repeat DST after 3-6 months to confirm lack of suppression are all plausible alternatives. However, 
evaluation of UFC and ACTH are associated with technical problems (89, 90) and the high dose DSTs have not been 
  
extensively employed for this problem. Midnight serum cortisol may be used as a second-line test, as it is cumbersome 
and expensive, even if it may correlate better than other tests with clinical conditions associated to hypercortisolism 
(123). Recent studies have shown that normal late-night salivary cortisol levels do not rule out subclinical Cushing‟s 
syndrome among patients with adrenal incidentalomas. Thus, the late night salivary cortisol cannot be presently 
included in the screening procedures for subclinical Cushing‟s syndrome until more data will become available (126-
128).   
A thorough assessment of the HPA axis in patients with clinically inapparent adrenal adenomas may show several 
combinations of abnormal tests pointing to ACTH-independence of cortisol secretion.   Different authors have used a 
number of criteria, often including a pair of altered test results (9, 13, 102, 104, 110, 116, 118, 119). A second abnormal  
test result of HPA axis function, such as a low or suppressed ACTH or a low dehydroepiandrosterone sulfate (DHEAS) 
concentration supports the diagnosis according to the AACE/AAES Guidelines (80). However, there are conflicting 
data that do not allow to conclude that low DHEAS concentration is a reliable, indirect marker of autonomous cortisol 
secretion (102-105, 109, 129-130). Moreover, DHEAS secretion declines with age physiologically, and this may 
hamper recognition of reduced DHEAS concentrations in an aged population (102, 129, 130). 
In summary, the dilemma between a strategy aiming to increase sensitivity and one oriented to favoring specificity in 
the screening of subclinical Cushing‟s syndrome remains unsolved. Since the long–term consequences of the mild 
cortisol excess that characterizes subclinical Cushing‟s syndrome have not been unequivocally defined, a recent 
provocative paper casted doubts on the value of extensive testing for this condition (16). In principle, the Panel accepts 
that there is insufficient data linking patient‟s outcome to the appointed diagnosis. In other terms, the relationships 
between endocrine findings and patient‟s phenotype remain to be elucidated (14). This complex issue is emphasized by 
the lack of a simple correlation between the results of preoperative tests of the HPA axis and the postoperative 
occurrence of corticotropic insufficiency that may be considered as a demonstration of the previous existence of some 
degree of cortisol excess (131). Thus, we are recommending use of stringent criteria to diagnose this condition to reduce 
false positive results that may have negative psychological and economic consequences, leading to further testing or 
even unnecessary surgery. 
The Panel suggests a flexible approach guided by clinical judgment. It seems biologically plausible to consider that 
cortisol levels after dexamethasone lower than 1.8 μg/dl (50 nmol/l) clearly exclude autonomous (ACTH-independent) 
cortisol secretion, whereas cortisol levels higher than 5 μg/dl (138 nmol/l) likely indicate subclinical Cushing‟s 
syndrome if no interfering conditions are present.  Cortisol values after dexamethasone between 1.8 μg/dl (50 nmol/l) 
and 5 μg/dl (138 nmol/l) may be considered as indeterminate. In such event, it may be considered to extend evaluation 
when features of Cushing‟s syndrome are present. The panel felt that these conclusions are sound following a line of 
reasoning analogous to that of overt Cushing‟s syndrome, but had to admit that there is insufficient evidence to support 
this strategy. 
Recommendations for hormonal assessment of adrenal incidentalomas are given in Table 6. 
 
 
 
 
 
NATURAL HISTORY AND MANAGEMENT 
 
 
Adrenal incidentaloma is not a uniform disease and its natural history varies depending on the pathologic classification 
of the adrenal mass. It is obvious that primary malignant adrenal tumors, and pheochromocytomas, can significantly 
  
affect patients‟ health. However, the potential harm associated with clinically inapparent adrenal adenomas, the most 
frequent type among adrenal incidentalomas is presently unclear (14).  
While the frequency of tumors that can be definitively dangerous for the patient is low among patients with adrenal 
incidentalomas who are currently referred to endocrinologists, it has to be considered that both pheochromocytoma and 
ACC are potentially lethal and patient‟s outcome can be greatly improved by timely adrenalectomy (77, 132). This 
justifies a low threshold for recommending surgery in doubtful cases. Patients bearing adrenal metastases have a 
clinical course depending on stage, grade, and site of the primary tumor (6). The other side of the problem is that most 
of the non-functioning ACC, which account for about 50% of all ACC, may be incidentally discovered (10) . ACC 
typically displays a rapid growth rate (> 2 cm per year) (17) and a poor outcome with a 5-year survival of less than 50% 
(132). At present, we do not know whether the prognosis of incidentally detected ACC is different from functioning 
ACC. However, the only hope of cure is the complete surgical removal of an early-stage tumor (132).  
Pheochromocytoma can also lead to significant morbidity and mortality if not diagnosed and treated appropriately. An 
increasing number of pheochromocytomas are clinically silent and nearly 30% of all pheochromocytomas show a 
nonspecific appearance at the imaging studies. These tumors are most often benign and the typical rate of growth is 
approximately 0.5 to 1.0 cm per year (17). Surgical resection is the treatment of choice, but it does not guarantee cure 
because recurrence can occur in as many as 17% of cases (133). Thus, a careful follow-up, including biochemical 
testing once a year, is advocated to ensure prompt diagnosis of local recurrence or metastatic spread (134).   
However, the large majority of adrenal incidentalomas remain untreated, since the lesions display the typical features of 
an adrenal adenoma without overt signs and symptoms of hormonal hypersecretion. The natural history and 
management of clinically inapparent adrenal adenomas will be reviewed in the present Position Statement. 
 
 
 
 
QUESTIONS 
1. What is the risk of malignant transformation of an adrenal incidentaloma?  
Available data on follow-up of patients with adrenal incidentalomas suggests that the large majority of adrenal lesions 
classified as benign at diagnosis remain stable over time. In series of patients with adrenal incidentalomas followed for 
an average of 4 years, 5-20% showed mass enlargement greater than 1 cm and/or appearance of another mass in the 
contralateral gland (10, 18, 114, 118, 135) Mass enlargement was generally limited to a 1-2 cm increase in diameter 
over a period of 1-3 years (10). The presence of endocrine abnormalities at diagnosis is not a reliable predictor of a 
possible increase in tumor size during follow-up, as previously thought (10, 118), since mass enlargement was also 
described in patients with non-secreting adrenal incidentalomas (14, 17). The threshold for qualifying an increase in 
size as significant is unknown, but it should be argued that most adrenal masses that exhibit a pattern of slow growth are 
not malignant. Moreover, occasional shrinkage, or even complete disappearance, of an adrenal mass have been also 
reported in about 4% of cases, most often when cystic lesions, haematomas, or adrenal pseudotumors were diagnosed 
(10, 136).  
In a recent review, Cawood et al. (16) found only 2 reports of a malignancy detected during follow-up of adrenal 
incidentalomas thought to be benign at diagnosis, a renal carcinoma metastasis (137) and a non-Hodgkin‟s lymphoma 
(118). Overall, the risk of an untreated adrenal incidentaloma, qualified as a benign lesion, subsequently developing 
malignancy appears to be very low, less than 1 out of 1000 (10, 16, 114, 135) . This figure indirectly points out that the 
current imaging strategy is adequate to ascertain the dignity of adrenal incidentalomas.  
 
  
2. What is the risk of evolution towards overt hypersecretion? 
Abnormal adrenal function that is not present at baseline may be detected during follow-up (17). The most common 
disorder reported during follow-up is the occurrence of autonomous cortisol secretion eventually leading to subclinical 
cortisol excess. The onset of catecholamine overproduction or hyperaldosteronism during long-tem follow-up is very 
rare (10). 
The studies that evaluated the risk of progression from subclinical to overt Cushing‟s syndrome are as a whole 
reassuring and demonstrate that this event occurs rarely, if ever. Development of overt Cushing‟s syndrome during 
follow-up was observed in a negligible number of cases, less than 1%, while appearance of silent biochemical 
alterations was reported in a percentage ranging from 0% to 11% across different studies (10, 96). Masses of 3 cm or 
greater are more likely to develop silent hyperfunction than smaller tumors, and the risk seems to plateau after 3 to 4 
years, even if it does not subside completely (118, 138). Unilateral uptake at baseline NP-59 scintigraphy as been 
associated with persistence and progression of biological SCCS (97,138). On the other hand, endocrine alterations may 
spontaneously normalize during follow-up (13, 136). This behavior raises the possibility of cyclical cortisol secretion 
by clinical inapparent adrenal adenomas (13). 
 
3. What are the morbidity and mortality of subclinical Cushing’s syndrome?  
Notwithstanding uncertainty regarding ascertainment of subclinical Cushing‟s syndrome, there is no doubt that many 
patients may be exposed to a chronic, albeit slight, cortisol excess (139). Thus, it is biologically plausible to assume that 
they should suffer from the classic complications of full-blown Cushing‟s syndrome, such as arterial hypertension, 
obesity, or diabetes. However, there is still scanty information on the long-term detrimental effects, if any, of silent 
hypercortisolism (96, 140-142). 
An increased frequency of hypertension, central obesity, impaired glucose tolerance or diabetes, hyperlipemia and 
osteoporosis have been described in patients with subclinical Cushing‟s syndrome in a number of retrospective, or 
cross-sectional studies (9, 96, 119-121, 123, 124, 141-147). The results of these studies suggest that subclinical 
Cushing‟s syndrome may be associated with the clinical phenotype of the insulin resistance syndrome that fosters a 
number of unwanted metabolic and vascular manifestations (141). However, the interpretations of these data must be 
considered with caution since there is the potential of confounding and referral bias due to the limitations in the design 
of the studies. An alternative hypothesis that adrenal incidentaloma may itself be an unrecognized manifestation of the 
metabolic syndrome can not be ruled out (148), even if a causal link between subclinical Cushing‟s syndrome and 
insulin resistance is the most plausible explanation for the available data (139). 
Despite the reported association between subclinical Cushing‟s syndrome and the metabolic syndrome, which carries an 
enhanced all-cause and cardiovascular mortality (149, 150), evidence of increased mortality in patients who have 
clinically inapparent adrenal adenomas and subclinical Cushing‟s syndrome is lacking. The (scarce) available data 
suggest that most patients with adrenal incidentalomas remain asymptomatic throughout life (139-142). The cause of 
death was mostly related to cardiovascular events, but it is unknown whether the mortality rate is higher than the 
general population (136, 139-142, 151). However, the existing follow-up studies have focused almost exclusively on 
the issues of potential malignant transformation and evolution of endocrine patterns. There are few studies addressing 
outcome measures, but interpretation of these follow-up studies is affected by their small sample size, and variable 
duration and modality of follow-up. The potential for ascertainment bias should be considered because many of these 
observations were made in small, retrospective series. The results of such studies are outlined in the following chapter. 
 
4. What management for subclinical Cushing’s syndrome? 
  
A number of underpowered studies reported improvement in either hypertension or hyperglycemia in some patients 
with subclinical Cushing‟s syndrome after adrenalectomy (119, 120, 130, 152, 153). In a case-control study, Erbil et al 
(154) compared the outcome of adrenalectomy between 28 patients with overt Cushing‟s syndrome and 11 patients with 
subclinical Cushing‟s syndrome and found quite unexpectedly that hypertension improved more frequently among 
patients with the subclinical syndrome. Tsuiki et al. (155) followed up 20 patients with subclinical Cushing‟s syndrome 
for 15-69 months, 10 of them were submitted to adrenalectomy and the remainders were managed conservatively. Eight 
patients benefitted from surgery in term of better control of hypertension and/or hyperglycemia while half of the non-
operated patients showed a worsening of their clinical conditions and the other remained unchanged. Toniato et al. 
(156) carried on a prospective study in which 45 patients with subclinical Cushing‟s syndrome were randomly selected 
to surgery (n=23) or conservative management (n=22); mean duration of follow-up was about 8 years. They found that 
diabetes and hypertension normalized or improved in about 2/3 of patients in the surgical group; on the other hand, 
some worsening of diabetes and hypertension was noted in conservatively managed patients. The conclusion of the 
authors that laparoscopic adrenalectomy appears more beneficial than conservative management for patients with 
subclinical Cushing‟s syndrome should be viewed with caution due to some methodological shortcomings of the study 
including the lack of a formal comparison between the patients who were operated and those who were not and the fact 
that medical treatment of associated clinical conditions was not standardized between groups. Sereg et al. (157) did a 
retrospective uncontrolled study, in which 47 out of 125 patients with clinically non-functioning adrenal adenomas 
underwent adrenalectomy while 78 patients were followed conservatively; these patients were re-assessed after a mean 
follow-up time of about 9 years (157). The frequency of cardiovascular or cerebrovascular events did not differ 
significantly between patients treated and not treated with adrenalectomy. At variance with the previous study, the 
authors did not find any beneficial effect of surgery, but it has to be pointed out that adrenalectomy was not 
recommended for treatment of subclinical Cushing‟s syndrome, which was diagnosed only in a minority of patients 
submitted to surgery. Recently, Chiodini et al. (158) published a retrospective controlled study on 108 patients followed 
for 18-48 months. Adrenalectomy was recommended to all patients with subclinical Cushing‟s syndrome and to all 
patients without but with mass size >4 cm, or size increasing by >1 cm during follow-up. However, some patients 
refused surgery, so 4 different groups were available for comparison at baseline and at the last follow-up (subclinical 
operated, subclinical not operated, non-subclinical operated and non-subclinical not operated). Adrenalectomy 
improved blood pressure and glucose levels in patients with subclinical Cushing‟s syndrome compared to patients 
treated conservatively.  To a lesser extent, adrenalectomy improved blood pressure also in patients without subclinical 
Cushing‟s syndrome compared to patients treated conservatively (158). This study suggests that surgery may be 
beneficial; however, clinical improvement was not restricted to patients with subclinical Cushing‟s syndrome casting 
some doubts on a cause and effect relationship. Moreover, it has to be pointed out that medical treatment was not 
standardized across the different groups. 
This inconsistent and incomplete evidence summarized in table 7 precludes any stringent recommendation for 
management of subclinical Cushing‟s syndrome. Limits of the available literature on the outcome of surgical treatment 
include heterogeneous definition of subclinical Cushing‟s syndrome, small sample size, retrospective and uncontrolled 
nature of most studies, variable duration of follow-up, inadequate definition of end-points and outcomes. In particular, 
no study compared the outcome of adrenalectomy with that of best medical management of associated diseases 
following specific treatment guidelines. Data from high-quality prospective trials are lacking to guide the optimal 
management of subclinical Cushing‟s syndrome and to indicate the superiority of a surgical or a non-surgical approach 
(1, 14, 17, 96). Until the risks and benefits of adrenalectomy are elucidated, it seems reasonable to elect for surgery 
younger patients with subclinical Cushing‟s syndrome who display diseases potentially attributable to cortisol excess 
(hypertension, diabetes, abdominal obesity and osteoporosis) that are of recent onset, or are resistant to optimal medical 
  
treatment, or are rapidly worsening (1, 14, 17, 96, 140). The Panel admits that this strategy is based on pragmatism and 
not on robust evidence; however, this commonsense advice has also been made also by Young (17). The AACE/AAES 
Medical Guidelines for the Management of Adrenal Incidentalomas reported likewise that in patients with subclinical 
Cushing‟s syndrome, until further evidence is available regarding the long-term benefits of adrenalectomy, surgical 
resection should be reserved for those with worsening of hypertension, abnormal glucose tolerance, dyslipidemia, or 
osteoporosis (recommendation with a low level of evidence) (80). The NIH state-of-the science statement suggested 
that either adrenalectomy or careful observation is a treatment option for patients with subclinical autonomous 
glucocorticoid hypersecretion. According to the NIH Panel, adrenalectomy has been demonstrated to correct the 
biochemical abnormalities, but its effect on long-term outcome and quality of life is unknown (6).  
 
5. What surgical technique for adrenalectomy? 
Laparoscopic adrenalectomy is a safe and effective procedure in skilled hands and it has become the surgical technique 
of choice for benign masses (80, 159). The advantages of laparoscopic adrenalectomy over traditional open 
adrenalectomy include a more comfortable postoperative course, a shorter hospital stay, rapid return to daily activities 
and superior cosmetic results. Controversy remains regarding the safety and effectiveness of laparoscopic 
adrenalectomy for large lesions and lesions presumed to be malignant. Several laparoscopic techniques have been 
developed but no studies demonstrate a consistent benefit of one laparoscopic approach (anterior or lateral 
transperitoneal, posterior retroperitoneal) over another (6). The rate of major complications from laparoscopic 
adrenalectomy is very low but not zero. The importance of expertise, and the existence of a learning curve should be 
recognized (160, 161).  
There is general consensus that patients with subclinical Cushing‟s syndrome require postoperative glucocorticoid 
replacement to prevent the risk of adrenal insufficiency (6, 80). However, steroid coverage may be required also in 
patients with nonfunctioning adenomas since no hormonal parameter, or combination of parameters, may predict the 
occurrence of post-surgical hypoadrenalism (96, 131). The need of steroid replacement has to be confirmed 1-2 months 
after surgery with appropriate testing. If post-surgical adrenal insufficiency is confirmed, steroid replacement could be 
subsequently tapered guided by clinical data and re-evaluation of the HPA axis every 3-6 months. It is pertinent to say 
that adrenal insufficiency may last for many months. 
 
6. How to perform follow-up? 
How to follow-up patients with adrenal incidentaloma is a controversial issue. The NIH state-of-the science statement 
suggested repeating the hormonal screening, with an overnight 1-mg DST and measurement of urine catecholamines 
and metabolites, annually for 4 years, as the risk of hyperfunction seems to plateau after that period. Further, it was 
considered reasonable in patients whose lesions have not been excised to repeat CT 6 to 12 months after the initial study 
and to discontinue radiologic evaluation of lesions that do not increase in size (6). In the AACE /AAES Medical 
Guidelines for the Management of Adrenal Incidentalomas, it is stated that patients with adrenal incidentalomas who do 
not fulfill the criteria for surgical resection need to have radiographic reevaluation at 3 to 6 months and then annually 
for 1 to 2 years. Hormonal evaluation should be performed at the time of diagnosis and then annually for 5 years (80). 
In an influential review, Young recommended to repeat imaging at 6, 12, and 24 months, but an earlier evaluation may 
be worthwhile when the mass is suspicious, while less frequent imaging during follow-up is reasonable for patients with 
small (<2 cm), uniform, hypodense cortical nodules provided they have no history of malignant disease (17). 
Adrenalectomy is advised if the mass enlarges by 1 cm or more, or if autonomous hormonal secretion develops during 
follow-up. However, Young correctly recognized that the yield and cost-effectiveness of repeated imaging at these 
intervals are uncertain (17). A recent radiological review suggests that no follow-up is needed when an adrenal mass 
  
has been qualified as a myelolipoma or cyst and that the stability of an adrenal mass for 1 year or more makes a benign 
diagnosis very likely (72bis). 
Since a benign adrenal incidentaloma undergoes malignant transformation rarely, if ever, and the risk of developing 
clinically significant hormone hyperfunction during follow-up should not be a major concern, a recent paper concluded 
that, based on available evidence, follow-up of adrenal incidentalomas initially considered to be benign and not-
functional are likely to result in significant costs, due to frequent false positive results, carries little clinical benefit and 
even confers a non-negligible risk of fatal cancer due to CT-associated radiation exposure (16). Thus, the authors 
recommend against follow-up of all adrenal incidentalomas with repeated imaging and hormone work-up as a routine 
measure. It is our experience that repeating imaging tests in masses with clear benign features (size ≤2 cm and density 
≤10 HU) is of limited utility. The bottom line is that the limited and incomplete evidence available precludes making 
any stringent recommendation for periodic hormonal testing and repeat imaging evaluation for follow-up purposes. 
The Panel agrees that the value of periodic hormonal screening is uncertain but, if felt necessary, the 1-mg DST may 
serve the purpose. In our opinion, however, patients who are no candidates for surgery should be followed up clinically 
to detect, treat, and control cardiovascular risk factors that are usually overrepresented in patients with adrenal 
incidentalomas, either because they are exposed to chronic cortisol excess or because of a referral bias (such patients 
are more likely to undergo imaging procedures). The simple and important task of advising lifestyle changes and 
effective medical treatment to reduce cardiovascular risk has to be highlighted. Accordingly, Nieman advocated 
surgical treatment for patients with mild hypercortisolism when medical treatment fails or there is progression of 
clinical features (162).  Patients who develop clinical signs of hormone excess, or experience worsening of their 
metabolic status and cardiovascular risk profile despite optimal medical treatment, should be re-tested for endocrine 
hyperfunction (163). 
Concerning imaging, we recommend to repeat a CT scan only once after 3 to 6 months, to be sure of not missing a 
tumor whose malignant potential was missed at diagnosis. Patients with small tumors, less than 2 cm, do not need 
further imaging in most cases, but for larger tumors the decision to proceed or not with follow-up imaging study should 
be judged on an individual basis, taking into consideration the characteristics of the mass, patient age and history and 
results of endocrine work-up (163). Patients with subclinical Cushing‟s syndrome who do not reach the treatment goals 
of associated diseases potentially linked to hypercortisolism (i.e., hypertension, diabetes) despite an adequate medical 
therapy, or patients with an adrenal incidentaloma showing a significant (>1 cm) increase in size should be offered 
surgery. We acknowledge that this clinically-oriented strategy is largely based on pragmatism, but has the merit of 
reducing costs and, possibly, increasing benefits compared to current strategies. Moreover, it takes into account the fact 
that many patients are worried if no follow-up is offered . 
Recommendations for the management of adrenal incidentalomas are given in Table 8. 
 
 
Declaration of interest: There is no conflict of interest that could be perceived as prejudicing the impartiality of the 
research reported. 
 
Funding: This research did not receive any specific grant from any funding agency in the public, commercial or not-
for-profit sector. 
 
Acknowledgements: We are grateful to the European Network for the Study of Adrenal Tumors (ENSAT; 
www.ensat.org) and the European Science Foundation (Research Networking Program ESF-ENSAT) for endorsing the 
study. 
 
 
 
  
References 
 
1. Aron DC. The adrenal incidentaloma: disease of modern technology and public health problem. 
Reviews in Endocrine & Metabolic Disorders 2001 2 335–342. 
2. GRADE Working Group website. http://www.gradeworkinggroup.org 
3. Atkins D, Best D, Briss PA, Eccles M, Falck-Ytter Y, Flottorp S, Guyatt GH, Harbour RT, 
Haugh MC, Henry D, Hill S, Jaeschke R, Leng G, Liberati A, Magrini N, Mason J, Middleton P, 
Mrukowicz J, O'Connell D, Oxman AD, Phillips B, Schünemann HJ, Edejer TT, Varonen H, Vist 
GE, Williams JW Jr & Zaza S; GRADE Working Group. Grading quality of evidence and strength 
of recommendations. British Medical Journal 2004 328 1490-1497. 
4. Swiglo BA, Murad MH, Schünemann HJ, Kunz R, Vigersky RA, Guyatt GH & Montori VM. A 
case for clarity, consistency, and helpfulness: stateof-the-art clinical practice guidelines in 
endocrinology using the grading of recommendations, assessment, development, and evaluation 
system. Journal of Clinical Endocrinology and Metabolism 2008 93 666-673. 
5. Mansmann G, Lau J, Balk E, Rothberg M, Miyachi Y & Bornstein SR. The clinically inapparent 
adrenal mass: update in diagnosis and management. Endocrine Reviews 2004 25 309-340. 
6. Grumbach MM, Biller BMK, Braunstein GD, Campbell KK, Carney JA, Godley PA, Harris EL, 
Lee JKT, Oertel YC, Posner MC, Schlechte JA & Wieand HS. Management of the clinically 
inapparent adrenal mass (“Incidentaloma”). Annals of Internal Medicine 2003 138 424-429. 
7. Kloos RT, Gross MD, Francis IR, Korobkin M & Shapiro B. Incidentally discovered adrenal 
masses. Endocrine Reviews 1995 16 460–484. 
8. Benitah N, Yeh BM, Qayyum A, Williams G, Breiman RS, Coakley FV. Minor morphologic 
abnormalities of adrenal glands at CT: prognostic importance in patients with lung cancer. 
Radiology 2005 235 517–22. 
9. Mantero F, Terzolo M, Arnaldi G, Osella G, Masini AM, Ali A, Giovagnetti M, Opocher G & 
Angeli A. A survey on adrenal incidentaloma in Italy. Study Group on Adrenal Tumors of the 
Italian Society of Endocrinology. Journal of Clinical Endocrinology and Metabolism 2000 85 637–
644. 
10. Barzon L, Sonino N, Fallo F, Palù G & Boscaro M. Prevalence and natural history of adrenal 
incidentalomas. European Journal of Endocrinology 2003 149 273-285. 
11. Bovio S, Cataldi A, Reimondo G, Sperone P, Novello S, Berruti A, Borasio P, Fava C, Dogliotti 
L, Scagliotti GV, Angeli A & Terzolo M. Prevalence of adrenal incidentaloma in a contemporary 
computerized tomography series Journal of Endocrinological Investigation 2006 29 298-302. 
12. Mayer SK, Oligny LL, Deal C, Yezbeck S, Gagnè N & Blanchard H. Childhood adrenocortical 
tumours: case series and reevaluation of prognosis – a 24-year experience. Journal of Pediatric 
Surgery 1997 32 911-915. 
13. Terzolo M, Osella G, Ali A, Borretta G, Cesario F, Paccotti P & Angeli A. Subclinical 
Cushing‟s syndrome in adrenal incidentaloma. Clinical Endocrinology 1998 48 89–97. 
14. Terzolo M, Bovio S, Pia A, Reimondo G & Angeli A. Management of adrenal incidentaloma. 
Best Practice & Research. Clinical Endocrinology & Metababolism 2009 23 233-243. 
15. Bernini G, Moretti A, Argenio G & Salvetti A. Primary aldosteronism in normokalemic patients 
with adrenal incidentalomas. European Journal of Endocrinology 2002 146 523–529. 
16. Cawood T J, Hunt P J, O'Shea D
 
, Cole D & Soule S. Recommended evaluation of adrenal 
incidentalomas is costly, has high false-positive rates and confers a risk of fatal cancer that is 
similar to the risk of the adrenal lesion becoming malignant; time for a rethink? European Journal 
of Endocrinology 2009 161 513-527.  
17. Young WF. The incidentally discovered adrenal mass. New England Journal of Medicine 2007 
356 601–610. 
18. Lam KY & Lo CY. Metastatic tumours of the adrenal glands: a 30-year experience in a teaching 
hospital. Clinical Endocrinology 2002 56 95–101. 
19. Francis IR, Smid A, Gross MD, Shapiro B, Naylor B & Glazer GM. Adrenal masses in 
oncologic patients: functional and morphologic evaluation. Radiology 1988 166 353–356. 
  
20. Lenert JT, Barnett Jr CC, Kudelka AP, Sellin RV, Gagel RF, Prieto VG, Skibber JM, Ross MI, 
Pisters PW, Curley SA, Evans DB & Lee JE. Evaluation and surgical resection of adrenal masses in 
patients with a history of extra-adrenal malignancy. Surgery 2001 130 1060–1067. 
21. Frilling A, Tecklenborg K, Weber F, Kuhl H, Muller S, Stamatis G & Broelsch C. Importance 
of adrenal incidentaloma in patient with a history of malignancy. Surgery 2004 136 1289-1296. 
22. Lee JE, Evans DB, Hickey RC, et al. Unknown primary cancer presenting as an adrenal mass: 
frequency and implications for diagnostic evaluation of adrenal incidentalomas. Surgery 1998 124 
1115–22. 
23. Michalkiewcz E, Sandrini B, Figueiredo B, Miranda ECM, Caran E, Oliveira-Filho AG, 
Marques R, Pianovski MAD, Lacerda L, Cristofani LM, Jenkins J, Rodriguez-Galindo C & Ribeiro 
RC. Clinical and outcome characteristics of children with adrenocortical tumors: a report from the 
international pediatric adrenocortical tumor registry. Journal of Clinical Oncology 2004 22 838-
845. 
24. Mazzuco TL, Bourdeau I & Lacroix A. Adrenal incidentalomas and subclinical Cushing‟s 
syndrome: diagnosis and treatment. Current Opinion in Endocrinology, Diabetes, and Obesity 2009 
16 203-210. 
25. Hamrahian AH, Ioachimescu AG, Remer EM, Motta-Ramirez G, Bogabathina H, Levin HS, 
Reddy S, Gill IS, Siperstein A & Bravo EL. Clinical utility of noncontrast computed tomography 
attenuation value (Hounsfield Units) to differentiate adrenal adenomas/hyperplasias from 
nonadenomas: Cleveland Clinic experience. Journal of Clinical Endocrinology and Metabolism 
2005 90 871–877. 
26. Yeh HC. Sonography of the adrenal glands: normal glands and small masses. American 
Journal of Roentgenology 1980 135 1167–1177. 
27. Suzuki K, Fujita K, Ushiyama T, Mugiya S, Kageyama S & Ishikawa A. Efficacy of an 
ultrasonic surgical system for laparoscopic adrenalectomy. Journal of Urology 1995 154 484–486. 
28. Abrams HL, Siegelman SS, Adams DF, Sanders R, Finberg HJ, Hessel SJ & McNeil BJ. 
Computed tomography versus ultrasound of the adrenal gland: a prospective study. Radiology 1982 
143 121–128. 
29. Suzuki Y, Sasagawa I, Suzuki, H, Izumi T, Kaneko H & Nakada T. The role of ultrasonography 
in the detection of adrenal masses: Comparison with computed tomography and magnetic resonance 
imaging. International Urology and Nephrology 2001 32 303–306. 
30. Fontana D, Porpiglia F, Destefanis P, Fiori C, Alı` A, Terzolo M,. Osella G & Angeli A. What 
is the role of ultrasonography in the follow up of adrenal incidentalomas? Urology 1999 54 612–
616. 
31. Blake MA, Kalra MK, Sweeney AT, Lucey BC, Maher MM, Sahani DV, Halpern EF, Mueller 
PR, Hahn PF & Boland GW. Distinguishing benign from malignant adrenal masses: multi–detector 
row CT protocol with 10-minute delay. Radiology 2006 238 578–585. 
32. Lee MJ, Hahn PF, Papanicolaou N, Egglin TK, Saini S, Mueller PR & Simeone JF. Benign and 
malignant adrenal masses: CT distinction with attenuation coefficients, size, and observer analysis. 
Radiology 1991 179 415–418. 
33. Korobkin M, Brodeur FJ, Francis IR, Quint LE, Dunnick NR & Londy F. CT time–attenuation 
washout curves of adrenal adenomas and nonadenomas. American Journal of Roentgenology 1998 
170 747–752. 
34. Pena CS, Boland GW, Hahn PF, Lee MJ & Mueller PR. Characterization of indeterminate 
(lipid-poor) adrenal masses: use of washout characteristics at contrast enhanced CT. Radiology 
2000 217  798–802. 
35. Caoili EM, Korobkin M, Francis IR, Cohan RH, Platt JF, Dunnick NR & Raghupathi KI. 
Adrenal masses: characterization with combined unenhanced and delayed enhanced CT. Radiology 
2002 222 629–633. 
36. Szolar DH & Kammerhuber FH. Adrenal adenomas and nonadenomas: assessment of washout 
at delayed contrast-enhanced CT. Radiology 1998 207 369–375. 
36 bis. Johnson PT, Horton KM, Fishman EK. Adrenal mass imaging with multidetector CT: 
pathologic conditions, pearls, and pitfalls. Radiographics 2009 29 1333-51. 
  
 
37. Korobkin M, Lombardi TJ, Aisen AM, Francis IR, Quint LE, Dunnick NR, Londy F, Shapiro B, 
Gross MD & Thompson NW. Characterization of adrenal masses with chemical shift and 
gadolinium-enhanced  MR imaging.  Radiology 1995 197 411-418. 
38. Outwater EK, Siegelman ES, Radecki PD, Piccoli CW & Mitchell DG. Distinction between 
benign and malignant adrenal masses: value of T1-weighted chemical-shift MR imaging. American 
Journal of Roentgenology 1995 165 579-583. 
39. Bilbey JH, McLoughlin RF, Kurkjian PS, Wilkins GE, Chan NH, Schmidt N & Singer J. MR 
imaging of adrenal masses: value of chemical-shift imaging for distinguishing adenomas from other 
tumors. American Journal of Roentgenology 1995  164  637-642. 
40. McNicholas MM, Lee MJ, Mayo-Smith WW, Hahn PF, Boland GW & Mueller PR. An 
imaging algorithm for the differential diagnosis of adrenal adenomas and metastases. American 
Journal of Roentgenology 1995 165 1453–1459. 
41. Heinz-Peer G, Hönigschnabl S, Schneider B, Niederle B, Kaserer K & Lechner G. 
Characterization of adrenal masses using MR imaging with histopathologic correlation. American 
Journal of Roentgenology 1999 173 15-22. 
42. Israel GM, Korobkin M, Wang C, Hecht EN & Krinsky GA. Comparison of unenhanced CT 
and chemical shift MRI in evaluating lipid-rich adrenal adenomas. American Journal of 
Roentgenology 2004 183 215–219. 
43. Haider MA, Ghai S, Jhaveri K & Lockwood G. Chemical shift MR imaging of hyperattenuating 
(>10 HU) adrenal masses: does it still have a role? Radiology 2004 231 711–716. 
44. Korobkin M. CT characterization of adrenal masses: the time has come. Radiology 2000 217 
629–632. 
45. Dunnick NR & Korobkin M. Imaging of adrenal incidentalmomas: current status. American 
Journal of Roentgenology 2002 179 559–568. 
46. Park BK, Kim CK, Kim B & Lee JH. Comparison of delayed enhanced CT and chemical shift 
MR for evaluating hyperattenuating incidental adrenal masses. Radiology 2007 243 760–765. 
47. Boland GW, Blake MA, MD, Hahn PF & Mayo-Smith WW. Incidental adrenal lesions: 
principles, techniques, and algorithms for imaging characterization. Radiology 2008 249 756-775. 
48. Rubello D, Bui C, Casara D, Gross MD, Fig LM & Shapiro B. Functional scintigraphy of the 
adrenal gland. European Journal of Endocrinology 2002 147 13–28. 
49. Carey JE, Thrall JH, Freitas JE & Beierwaltes WH. Absorbed dose to the human adrenals from 
lodomethylnorcholesterol (I-131) “NP-59”: concise communication. Journal of Nuclear Medicine 
1979 20 60–62. 
50. Gross MD, Shapiro B, Francis IR, Glazer GM, Bree RL, Arcomano MA, Schteingart DE, Mc 
Leod MK, Sanfield JA & Thompson NW. Scintigrafic evaluation of clinically silent adrenal 
masses. Journal of Nuclear Medicine 1994 35 1145-1152. 
51. Gross MD, Shapiro B, Bouffard AJ, Glazer GM, Francis IR, Wilton GP, Khafagi F, Sonda LP 
Distinguishing benign from malignant euadrenal masses. Ann Intern Med 1998 109: 613-618. 
52. Falke TH & Sandler MP. Classification of silent adrenal masses: time to get practical. Journal 
of Nuclear Medicine 1994 35 1152-1154. 
53. Barzon L, Scaroni C, Sonino N, Fallo F, Gregianin M, Macrì C, Boscaro M (1988) Incidentally 
discovered adrenal tumors: endocrine and scintigraphic correlates. Journal of Clinical 
Endocrinology and Metabolism 83 55-62. 
54. Boland GW, Goldberg MA, Lee MJ, Mayo-Smith WW, Dixon J, McNicholas MM & Mueller 
PR. Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-
deoxy-D-glucose. Radiology 1995 194 131-134. 
55. Erasmus JJ, Patz EF Jr, McAdams HP, Murray JG, Herndon J, Coleman RE & Goodman PC. 
Evaluation of adrenal masses in patients with bronchogenic carcinoma using 18F-
fluorodeoxyglucose positron emission tomography. American Journal of Roentgenology 1997 168 
1357-1360. 
  
56. Maurea S, Mainolfi C, Bazzicalupo L, Panico MR, Imparato C, Alfano B, Ziviello M & 
Salvatore M. Imaging of adrenal tumors using FDG-PET: comparison of benign and malignant 
lesions. American Journal of Roentgenology 1999 173 25–29. 
57. Yun M, Kim W, Alnafisi N, Lacorte L, Jang S & Alavi A. 18F-FDG PET in characterizing 
adrenal lesions detected on CT or MRI. Journal of Nuclear Medicine 2001 42 1795–1799. 
58. Tenenbaum F, Groussin L, Foehrenbach H, Tissier F, Gouya H, Bertherat J, Dousset B, 
Legmann P, Richard B & Bertagna X.  18F-fluorodeoxyglucose positron emission tomography as a 
diagnostic tool for malignancy of adrenocortical tumours? Preliminary results in 13 consecutive 
patients. European Journal of Endocrinology 2004 150 789–792. 
59. Groussin L, Bonardel G, Silvera S, Tissier F, Coste J, Abiven G, Libe R, Bienvenu M, Alberini 
JL, Salenave S, Bouchard P, Bertherat J, Dousset B, Legmann P, Richard B, Foehrenbach H, 
Bertagna X & Tenenbaum F. 18F-Fluorodeoxyglucose positron emission tomography for the 
diagnosis of adrenocortical tumors: a prospective study in 77 operated patients. Journal of Clinical 
Endocrinology and Metabolism 2009 94 1713-1722. 
60. Nunes MN, Rault A, Teynie J, Valli N, Guyot M, Gaye D, Belleannee  G, Tabarin A. 18F-FDG 
PET for the Identification of Adrenocortical Carcinomas among Indeterminate Adrenal Tumors at 
Computed Tomography Scanning. World J Surg 2010 34 1506–1510. 
61. Tessonnier L, Sebag F, Palazzo FF et al Does 18F-FDG PET/CT add diagnostic accuracy in 
incidentally identified nonsecreting adrenal tumours? Eur J Nucl Med Mol Imaging 2008 35 2018–
2025. 
62. Metser U, Miller E, Lerman H, Lievshitz G, Avital S & Even-Sapir E. 18F-FDG PET/CT in the 
evaluation of adrenal masses. Journal of Nuclear Medicine 2006 47 32–37.  
63. Caoili EM, Korobkin M, Brown RK, Mackie G & Shulkin BL. Differentiating adrenal 
adenomas from nonadenomas using (18)F-FDG PET/CT: quantitative and qualitative evaluation. 
Academic Radiology 2007 14 468–475.  
64. Blake MA, Slattery JM, Kalra MK, Halpern EF, Fischman AJ, Mueller PR & Boland GW. 
Adrenal lesions: characterization with fused PET/CT image in patients with proved or suspected 
malignancy--initial experience. Radiology 2006 238 970-977. 
65. Minn H, Salonen A, Friberg J, Roivainen A, Viljanen T, Långsjö J, Salmi J, Välimäki M, 
Någren K & Nuutila P. Imaging of adrenal incidentalomas with PET using (11)C-metomidate and 
(18)F-FDG. Journal of Nuclear Medicine 2004 45 972–979. 
66. Hennings J, Lindhe O, Bergström M, Långström B, Sundin A & Hellman P. [11C]Metomidate 
positron emission tomography of adrenocortical tumors in correlation with histopathological 
findings. Journal of Clinical Endocrinology and Metabolism  2006 91 1410–1414. 
67. Hahner S, Stuermer A, Kreissl M, Reiners C, Fassnacht M, Haenscheid H, Beuschlein F, Zink 
M, Lang K, Allolio B & Schirbel A. [123 I]Iodometomidate for molecular imaging of 
adrenocortical cytochrome P450 family 11B enzymes. Journal of Clinical Endocrinology and 
Metabolism 2008 93 2358-2365. 
68. Bernardino ME, Walther MM, Phillips VM, Graham SD Jr, Sewell CW, Gedgaudas-McClees 
K, Baumgartner BR, Torres WE & Erwin BC. CT-guided adrenal biopsy: accuracy, safety, and 
indications. American Journal of Roentgenology 1985 144 67–69. 
69. Welch TJ, Sheedy PF, Stephens DH, Johnson CM & Swensen SJ. Percutaneous adrenal biopsy: 
review of a 10-year experience. Radiology 1994 193 341–344. 
70. Harisinghani MG, Maher MM, Hahn PF, Gervais DA, Jhaveri K, Varghese J & Mueller PR. 
Predictive value of benign percutaneous adrenal biopsies in oncology patients. Clinical Radiology 
2002 57 898–901. 
71. Quayle FJ, Spitler JA, Pierce RA, Lairmore TC, Moley JF & Brunt LM. Needle biopsy of 
incidentally discovered adrenal masses is rarely informative and potentially hazardous. Surgery 
2007 142 497-502. 
72. Paulsen SD, Nghiem HV, Korobkin M, Caoili EM & Higgins EJ. Changing role of imaging-
guided percutaneous biopsy of adrenal masses: evaluation of 50 adrenal biopsies. American 
Journal of Roentgenology 2004 182 1033–1037 
  
72bis. Berland LL, Silverman SG, Gore RM, Mayo-Smith WW, Megibow AJ, Yee J, Brink JA, 
Mark E. Baker ME, Michael P. Federle MP, Foley WD, Francis IR, Herts BR, Israel GM, Glenn 
Krinsky G, Platt JF, Shuman WP, Taylor AJ. Managing incidental findings on abdominal CT: white 
paper of the ACR incidental findings committee. J Am Coll Radiol 2010 7 754-773. 
73. Casola G, Nicolet V, vanSonnenberg E, Withers C, Bretagnolle M, Saba RM, Bret PM. 
Unsuspected pheochromocytoma: risk of blood-pressure alterations during percutaneous adrenal 
biopsy. Radiology 1986 159 733-5. 
74. Lenders JW, Pacak K, Walther MM, Linehan WM, Mannelli M, Friberg P, Keiser HR, 
Goldstein DS & Eisenhofer G. Biochemical diagnosis of pheochromocytoma: which is the best 
test? Journal of the American Medical Association 2002 287 1427-1434. 
75. Boyle JG, Davidson DF, Perry CG & Connell JM. Comparison of diagnostic accuracy of 
urinary free metanephrines, vanillyl mandel acid and cathecolamines and plasma catecolamines for 
diagnosis of phaeochromocytoma. Journal of Clinical Endocrinology and Metabolism 2007 92 
4602-4608. 
76. Eisenhofer G, Goldstein DS, Walther MM, Friberg P, Lenders JW, Keiser HR & Pacak K. 
Biochemical diagnosis of pheochromocytoma: how to distinguish true- from false-positive test 
results. Journal of Clinical Endocrinology and Metabolism 2003 88 2656-2666. 
77. Lenders JW, Eisenhofer G, Mannelli M & Pacak K. Phaeochromocytoma. Lancet 2005 366 
665-675. 
78. Pacak K, Eisenhofer G, Ahlman H, Bornstein SR, Gimenez-Roqueplo AP, Grossman AB, 
Kimura N, Mannelli M, McNicol AM & Tischler AS. Phaeochromocytoma: recommendations for 
clinical practice from the First International Symposium. Nature Clinical Practice. Endocrinology 
& Metabolism 2006 3 92-102.  
79. Funder JW, Carey RM, Fardella C, Gomez-Sanchez CE, Mantero F, Stowasser M, Young WF 
& Montori VM. Case detection, diagnosis, and treatment of patients with primary aldosteronism: an 
Endocrine Society clinical practice guideline. Journal of Clinical Endocrinology and Metabolism 
2008 93 3266-3281. 
80. Zeiger MA, Thompson GB, Duh QY, Hamrahian AH, Angelos P, Elaraj D, Fishman E & 
Kharlip J. The American Association of Clinical Endocrinologists and American Association of 
Endocrine Surgeons medical guidelines for the management of adrenal incidentalomas. Endocrine 
Practice 2009 15 1-20.  
81. Médeau V, Moreau F, Trinquart L, Clemessy M, Wémeau JL, Vantyghem MC, Plouin PF & 
Reznik Y. Clinical and biochemical characteristics of normotensive patients with primary 
aldosteronism: a comparison with hypertensive cases. Clinical Endocrinology 2008 69 20-28. 
82. Young WF. Primary aldosteronism: renaissance of a syndrome. Clinical Endocrinology 2007 66 
607-618. 
83. Montori VM & Young WF Jr. Use of plasma aldosteron concentration-to-plasma renin activity 
ratio as a screening test for primary hyperaldosteronism. A systematic review of the literature. 
Endocrinology and Metabolism Clinics of North America 2002 31 619-632.  
84. Mulatero P, Stowaser M, Loh KC, Fardella CE, Gordon RD, Mosso L, Gomez-Sanchez CE, 
Veglio F & Young WF Jr. Increased diagnosis of primary hyperaldosteronism in centers from five 
continents. Journal of Clinical Endocrinology and Metabolism 2004 89 1045-1950. 
85. Stowasser M & Gordon RD. The aldosterone-renin ratio for screening for primary 
hyperaldosteronism. Endocrinologist 2004 14 267-276. 
86. Tiu SC, Choi CH, Shek CC, Ng YW, Cyhan FK, Ng CM & Kong AP. The use of aldosterone-
renin ratio as a diagnostic test for primary hyperaldosteronism and its test characteristic under 
different conditions of blood sampling. Journal of Clinical Endocrinology and Metabolism 2005 90 
72-78. 
87. Perschel FH, Schemer R, Seiler L, Reincke M, Deinum J, Maser-Gluth C, Mechelhoff D, 
Tauber R & Diederich S. Rapid screening test for primary hyperaldosteronism: ratio of plasma 
aldosterone to renin concentration determined by fully automated chemiluminescence 
immunoassays. Clinical Chemistry 2004 50 1650-1655.  
  
88. Ferrari P, Shaw SG, Nicod J, Saner E & Nussberger J. Active renin versus plasma renin activity 
to define aldosterone-to-renin ratio for primary aldosteronism. Journal of hypertension 2004 22 
377-381. 
89. Nieman LK, Biller BMK, Findling JW, Newell-Price J, Savage M, Stewart PM & Montori VM. 
The diagnosis of Cushing‟s syndrome: an Endocrine Society Clinical Practice Guideline. Journal of 
Clinical Endocrinology and Metabolism 2008 93 1526-1540. 
90. Arnaldi G, Angeli A, Atkinson AB, Bertagna X, Cavagnini F, Chrousos GP, Fava GA, Findling 
JW, Gaillard RC, Grossman AB, Kola B, Lacroix A, Mancini T, Mantero F, Newell-Price J, 
Nieman LK, Sonino N, Vance ML, Giustina A & Boscaro M. Diagnosis and complication‟s of 
Cushing‟s syndrome: A consensus statement. Journal of Clinical Endocrinology and Metabolism 
2003 88 5593-5602.  
91. Raff H & Findling JW. A physiologic approach to diagnosis of the Cushing Syndrome. Annals 
of Internal Medicine 2003 138 980-991. 
92. Wood PJ, Barth JH, Frredman DB, Perry L & Sheridan B. Evidence for the low dose 
dexamethasone suppression test to screen for Cushing‟s syndrome-recommendations for a protocol 
for biochemistry laboratories. Annals of Clinical Biochemestry 1997 34 222-229. 
93. Newell Price J, Bertagna X, Grossman AB & Nieman LK. Cushing‟s syndrome. Lancet 2006 
367 1605-1617. 
94. Pecori Giraldi F, Ambrogio AG, De martin M, Fatti LM, Scacchi M & Cavagnini F. Specificity 
of first-line tests for the diagnosis of Cushing‟s syndrome: assessment in a large series. Journal of 
Clinical Endocrinology and Metabolism 2007 92 4123-4129. 
95. Elamin MB, Murad MH, Mullan R, Erickson D, Harris K, Nadeem S, Ennis R, Erwin PJ & 
Montori VM. Accuracy of diagnostic tests for Cushing‟s syndrome: a systematic review and 
metaanalyses. Journal of Clinical Endocrinology and Metabolism 2008 93 1553-1562. 
96. Terzolo M, Bovio S, Reimondo G, Pia A, Osella G, Borretta G & Angeli A. Subclinical 
Cushing's syndrome in adrenal incidentalomas. Endocrinology and Metabolism Clinics of North 
America 2005 34 423-439. 
97. Fagour C, Bardet S, Rohmer V, Arimone Y, Lecomte P, Valli N, Tabarin A. Usefulness of 
adrenal scintigraphy in the follow-up of adrenocortical incidentalomas: a prospective multicenter 
study. European Journal of Endocrinology 2009 160 257–264. 
98. Lacroix A, Ndiaye N, Tremblay J & Hamet P. Ectopic and abnormal hormone receptors in 
adrenal Cushing‟s syndrome. Endocrine Reviews 2001 22 75-110.  
99. Herrera MF, Grant CS, van Heerden JA, Sheedy PF & Ilstrup DM. Incidentally discovered 
adrenal tumors: an institutional perspective. Surgery 1991 110 1014-1021. 
100. Reincke M, Nieke J, Krestin GP, Saeger W, Allolio B & Winkelmann W. Preclinical 
Cushing's syndrome in adrenal "incidentalomas": comparison with adrenal Cushing's syndrome. 
Journal of Clinical Endocrinology and Metabolism 1992 75 826-832. 
101. Caplan RH, Strutt PJ & Wickus GG. Subclinical hormone secretion by incidentally discovered 
adrenal masses. Archives of Surgery 1994 129 291-296. 
102. Osella G, Terzolo M, Borretta G, Magro G, Alí A, Piovesan A, Paccotti P & Angeli A. 
Endocrine evaluation of incidentally discovered adrenal masses (incidentalomas). Journal of 
Clinical Endocrinology and Metabolism 1994 79 1532-1539. 
103. Flecchia D, Mazza E, Carlini M, Blatto A, Olivieri F, Serra G, Camanni F & Messina M. 
Reduced serum levels of dehydroepiandrosterone sulphate in adrenal incidentalomas: a marker of 
adrenocortical tumour. Clinical Endocrinology 1995 42 129-134. 
104. Ambrosi B, Peverelli S, Passini E, Re T, Ferrario R, Colombo P, Sartorio A & Faglia G. 
Abnormalities of endocrine function in patients with clinically "silent" adrenal masses. European 
Journal of Endocrinology 1995 132 422-428. 
105. Bardet S, Rohmer V, Murat A, Guillemot C, Maréchaud R, Chupin M, Lecomte P, Simon D, 
Delemer B, Schneebelli S, Beutter D, Jacquin V, Peltier P & Charbonnel B. 131I-6 beta-
  
iodomethylnorcholesterol scintigraphy: an assessment of its role in the investigation of 
adrenocortical incidentalomas. Clinical Endocrinology 1996 44 587-596. 
106. Linos DA, Stylopoulos N & Raptis SA. Adrenaloma: a call for more aggressive management. 
World Journal of Surgery 1996 20 788-92. 
107. Bondanelli M, Campo M, Trasforini G, Ambrosio MR, Zatelli MC, Franceschetti P, Valentini 
A, Pansini R & degli Uberti EC. Evaluation of hormonal function in a series of incidentally 
discovered adrenal masses. Metabolism 1997 46 107-113. 
108. Kasperlik-Zeluska AA, Rosłonowska E, Słowinska-Srzednicka J, Migdalska B, Jeske W, 
Makowska A & Snochowska H. Incidentally discovered adrenal mass (incidentaloma): 
investigation and management of 208 patients. Clinical Endocrinology 1997 46 29-37. 
109. Tsagarakis S, Roboti C, Kokkoris P, Vasiliou V, Alevizaki C & Thalassinos N. Elevated post-
dexamethasone suppression cortisol concentrations correlate with hormonal alterations of the 
hypothalamo-pituitary adrenal axis in patients with adrenal incidentalomas. Clinical Endocrinology 
1998 49 165-171. 
110. Rossi R, Tauchmanova L, Luciano A, Di Martino M, Battista C, Del Viscovo L, Nuzzo V & 
Lombardi G. Subclinical Cushing's syndrome in patients with adrenal incidentaloma: clinical and 
biochemical features. Journal of Clinical Endocrinology and Metabolism 2000 85 1440-1448. 
111. Favia G, Lumachi F, Basso S & D'Amico DF. Management of incidentally discovered adrenal 
masses and risk of malignancy. Surgery 2000 128 918-924. 
112. Tanabe A, Naruse M, Nishikawa T, Yoshimoto T, Shimizu T, Seki T, Takagi S, Imaki T & 
Takano K. Autonomy of cortisol secretion in clinically silent adrenal incidentaloma. Hormone and 
Metabolic Research 2001 33 444-450. 
113. Midorikawa S, Sanada H, Hashimoto S, Suzuki T, Watanabe T & Sasano H. Analysis of 
cortisol secretion in hormonally inactive adrenocortical incidentalomas: study of in vitro steroid 
secretion and immunohistochemical localization of steroidogenic enzymes. Endocrine Journal 2001 
48 167-174. 
114. Grossrubatscher E, Vignati F, Possa M & Loli P. The natural history of incidentally discovered 
adrenocortical adenomas: a retrospective evaluation. Journal of Endocrinological Investigation 
2001 24 846-855. 
115. Valli N, Catargi B, Ronci N, Vergnot V, Leccia F, Ferriere JM, Chene G, Grenier N, Laurent F 
& Tabarin A. Biochemical screening for subclinical cortisol-secreting adenomas amongst adrenal 
incidentalomas. European Journal of Endocrinology 2001 144 401-408. 
116. Barzon L, Fallo F, Sonino N & Boscaro M. Development of overt Cushing's syndrome in 
patients with adrenal incidentaloma. European Journal of Endocrinology 2002 146 61-66. 
117. Bülow B & Ahrén B. Swedish Research Council Study Group of Endocrine Abdominal 
Tumours. Adrenal incidentaloma--experience of a standardized diagnostic programme in the 
Swedish prospective study. Journal of Internal Medicine 2002 252 239-246. 
118. Libè R, Dall'Asta C, Barbetta L, Baccarelli A, Beck-Peccoz P & Ambrosi B. Long-term 
follow-up study of patients with adrenal incidentalomas. European Journal of Endocrinology 2002 
147 489-494. 
119. Tauchmanovà L, Rossi R, Biondi B, Pulcrano M, Nuzzo V, Palmieri EA, Fazio S & Lombardi 
G. Patients with subclinical Cushing's syndrome due to adrenal adenoma have increased 
cardiovascular risk. Journal of Clinical Endocrinology and Metabolism 2002 87 4872-4878. 
120. Emral R, Uysal AR, Asik M, Gullu S, Corapcioglu D, Tonyukuk V & Erdogan G. Prevalence 
of subclinical Cushing's syndrome in 70 patients with adrenal incidentaloma: clinical, biochemical 
and surgical outcomes. Endocrine Journal 2003 50 399-408. 
121. Hadjidakis D, Tsagarakis S, Roboti C, Sfakianakis M, Iconomidou V, Raptis SA & 
Thalassinos N. Does subclinical hypercortisolism adversely affect the bone mineral density of 
patients with adrenal incidentalomas? Clinical Endocrinology 2003 58 72-77. 
122. Katabami T, Obi R, Shirai N, Naito S & Saito N. Discrepancies in results of low-and high-
dose dexamethasone suppression tests for diagnosing preclinical Cushing's syndrome. Endocrine 
Journal. 2005 52 463-469. 
  
123. Terzolo M, Bovio S, Pia A, Conton PA, Reimondo G, Dall'Asta C, Bemporad D, Angeli A, 
Opocher G, Mannelli M, Ambrosi B & Mantero F. Midnight serum cortisol as a marker of 
increased cardiovascular risk in patients with a clinically inapparent adrenal adenoma. European 
Journal of Endocrinology 2005 153 307-315. 
124. Tabarin A, Bardet S, Bertherat J, Dupas B, Chabre O, Hamoir E, Laurent F, Tenenbaum F, 
Cazalda M, Lefebvre H, Valli N & Rohmer V. Exploration and management of adrenal 
incidentalomas. French Society of Endocrinology Consensus. Annales d’Endocrinologie 2008 69 
487-500. 
125. Reimondo G, Allasino B, Bovio S, Saba L, Ardito A, Angeli A, Terzolo M. Pros and cons of 
dexamethasone suppression test for screening of subclinical Cushing‟s syndrome in patients with 
adrenal incidentalomas. Journal of  Endocrinological Investigation 2011 34 e1-e5   
126. Doi M, Sekizawa N, Tani Y, Tsuchiya K, Kouyama R, Tateno T, Izumiyama H, Yoshimoto T 
& Hirata Y. Late-night salivary cortisol as a screening test for the diagnosis of Cushing's syndrome 
in Japan. Endocrine Journal 2008 55 121-126. 
127. Masserini B, Morelli V, Bergamaschi S, Ermetici F, Eller-Vainicher C, Barbieri AM, Maffini 
MA, Scillitani A, Ambrosi B, Beck-Peccoz P & Chiodini I. The limited role of midnight salivary 
cortisol levels in the diagnosis of subclinical hypercortisolism in patients with adrenal 
incidentaloma. European Journal of Endocrinology 2009 160 87-92. 
128. Nunes ML, Vattaut S, Corcuff JB, Rault A, Loiseau H, Gatta B, Valli N, Letenneur L & 
Tabarin A. Late-night salivary cortisol for diagnosis of overt and subclinical Cushing's syndrome in 
hospitalized and ambulatory patients. Journal of Clinical Endocrinology and Metabolism 2009 94 
456-462. 
129. Bencsik Z, Szabolcs I, Kovacs Z, Ferencz A, Voros A, Kaszas I, Bor K, Gonczi J, Goth M, 
Kovacs L, Dohan O & Szilagyi G. Low dehydroepiandrosterone sulfate (DHEA-S) level is not a 
good predictor of hormonal activity in nonselected patients with incidentally detected adrenal 
tumors. Journal of Clinical Endocrinology and Metabolism 1996 81 1726–1729. 
130. Terzolo M, Osella G, Alı` A, Borretta G, Magro GP, Termine A, Paccotti P & Angeli A. 
Different patterns of steroid secretion in patients with adrenal incidentaloma. Journal of Clinical 
Endocrinology and Metabolism 1996 81 740–744. 
131. Eller-Vainicher C, Morelli V, Salcuni AS, Torlontano M, Coletti F, Iorio L, Cuttitta A, 
Ambrosio A, Vicentini L, Carnevale V, Beck-Peccoz P, Arosio M, Ambrosi B, Scillitani A & 
Chiodini I. Post-surgical hypocortisolism after removal of an adrenal incidentaloma: is it 
predictable by an accurate endocrinological work-up before surgery? European Journal of 
Endocrinology 2010 162 91-99. 
132. Allolio B & Fassnacht M. Clinical review: Adrenocortical carcinoma: clinical update. Journal 
of Clinical Endocrinology and Metabolism 2006 91 2027-2037. 
133. Amar L, Peyrard S, Rossignol P, Zinzindohoue F, Gimenez-Roqueplo AP & Plouin PF. 
Changes in urinary total metanephrine excretion in recurrent and malignant pheochromocytomas 
and secreting paragangliomas. Annals of the New York Academy of Sciences 2006 1073 383-391. 
134. Eisenhofer G, Siegert G, Kotzerke J, Bornstein SR & Pack K. Current progress and future 
challenges in the biochemical diagnosis and treatment of pheochromocytoma and paragangliomas. 
Hormone and Metabolic Research 2008 40 329-337. 
135. Bulow B, Jansson S, Juhlin C, Steen L, Thoren M, Wahrenberg H, Valdemarsson S & Ahren 
B. Adrenal incidentaloma - follow-up results from a Swedish prospective study. European Journal 
of Endocrinology 2006 154 419-423. 
136. Bernini GP, Moretti A, Oriandini C, Bardini M, Taurino C & Salvetti A. Long-term 
morphological and hormonal follow-up in a single unit on 115 patients with adrenal incidentalomas. 
British Journal of Cancer 2005 92 1104-1109. 
137. Tsvetov G, Shimon I & Benbassat C. Adrenal incidentaloma: clinical characteristics and 
comparison between patients with and without extraadrenal malignancy. Journal of 
Endocrinological Investigation 2007 30 647–652. 
138. Barzon L, Scaroni C, Sonino N, Fallo F, Paoletta A & Boscaro M. Risk factors and long-term 
follow-up of adrenal incidentalomas. Journal of Clinical Endocrinology and Metabolism 1999 84 
  
520-526. 
139. Angeli A & Terzolo M. Adrenal incidentaloma--a modern disease with old complications. 
Journal of Clinical Endocrinology and Metabolism 2002 87 4869-4871. 
140. Reincke M. Subclinical Cushing's syndrome. Endocrinology and Metabolism Clinics of North 
America 2000 29 43-56.  
141. Young WF. Management approaches to adrenal incidentalomas. A view from Rochester, 
Minnesota. Endocrinology and Metabolism Clinics of North America 2000 29 159-185. 
142. Giordano R, Marinazzo E, Berardelli R, Picu A, Maccario M, Ghigo E, Arvat E. Long-term 
morphological, hormonal, and clinical follow-up in a single unit on 118 patients with adrenal 
incidentalomas. European Journal of Endocrinology 2010 162 779-85. 
143. Terzolo M, Pia A, Alì A, Osella G, Reimondo G, Bovio S, Daffara F, Procopio M, Paccotti P, 
Borretta G & Angeli A. Adrenal incidentaloma: a new cause of the metabolic syndrome? Journal of 
Clinical Endocrinology and Metabolism  2002 87 998-1003. 
144. Chiodini I, Torlontano M,Carnevale V, Guglielmi G, Cammisa M, Trischitta V & Scillitani A 
Bone loss rate in adrenal incidentalomas: a longitudinal study. Journal of Clinical Endocrinology 
and Metabolism 2001 86 5337-5341. 
145. Chiodini I, Guglielmi G, Battista C, Carnevale V, Torlontano M, Cammisa M, Trischitta V & 
Scillitani A. Spinal volumetric bone mineral density and vertebral fractures in female patients with 
adrenal incidentalomas: the effects of subclinical hypercortisolism and gonadal status. Journal of 
Clinical Endocrinology and Metabolism 2004 89 2237-2241. 
146. Chiodini I, Viti R, Coletti F, Guglielmi G, Battista C, Ermetici F, Morelli V, Salcuni A, 
Carnevale V, Urbano F, Muscarella S, Ambrosi B, Arosio M, Beck-Peccoz P & Scillitani A. 
Eugonadal male patients with adrenal incidentalomas and subclinical hypercortisolism have 
increased rate of vertebral fractures. Clinical Endocrinology 2009 70 208-213.  
147. Chiodini I, Morelli V, Masserini B, Salcuni AS, Eller-Vainicher C, Viti R, Coletti F, 
Guglielmi G, Battista C, Carnevale V, Iorio L, Beck-Peccoz P, Arosio M, Ambrosi B & Scillitani 
A. Bone mineral density, prevalence of vertebral fractures, and bone quality in patients with adrenal 
incidentalomas with and without subclinical hypercortisolism: an Italian multicenter study. Journal 
of Clinical Endocrinology and Metabolism  2009 94 3207-3214.  
148. Reincke M, Fassnacht M, Väth S, Mora P & Allolio B. Adrenal incidentalomas: a 
manifestation of the metabolic syndrome? Endocrine Research 1996 22 757-761.  
149. Alexander CM, Landsman PB, Teutsch SM & Haffner SM. NCEP-defined metabolic 
syndrome, diabetes, and prevalence of coronary heart disease among NHANES III participants age 
50 years and older. Third National Health and Nutrition Examination Survey (NHANES III); 
National Cholesterol Education Program (NCEP). Diabetes  2003 52 1210-1214. 
150. Malik S, Wong ND, Franklin SS, Kamath TV, L'Italien GJ, Pio JR & Williams GR. 
Circulation. Impact of the metabolic syndrome on mortality from coronary heart disease, 
cardiovascular disease, and all causes in United States adults. 2004 110 1245-1250.  
151. Sirén J, Tervahartiala P, Sivula A & Haapiainen R. Natural course of adrenal incidentalomas: 
seven-year follow-up study. World Journal of Surgery 2000 24 579-82. 
152. Midorikawa S, Sanada H, Hashimoto S, Suzuki T & Watanabe T. The improvement of insulin 
resistance in patients with adrenal incidentaloma by surgical resection. Clinical Endocrinology 
2001 54 797-804. 
153. Mitchell IC, Auchus RJ, Juneja K, Chang AY, Holt SA, Snyder WH 3
rd
 & Nwariaku FE. 
Subclinical Cushing's syndrome" is not subclinical: improvement after adrenalectomy in 9 patients. 
Surgery 2007 142 900-905. 
154. Erbil Y, Ademoğlu E, Ozbey N, Barbaros U, Yanik BT, Salmaslioğlu A, Bozbora A & 
Ozarmağan S. Evaluation of the cardiovascular risk in patients with subclinical Cushing syndrome 
before and after surgery. World Journal of Surgery  2006 30 1665-1671. 
155. Tsuiki M, Tanabe A, Takagi S, Naruse M & Takano K. Cardiovascular risks and their long-
term clinical outcome in patients with subclinical Cushing's syndrome. Endocrine Journal 2008 55 
737-745.  
156. Toniato A, Merante-Boschin I, Opocher G, Pelizzo MR, Schiavi F & Ballotta E. Surgical 
  
versus conservative management for subclinical Cushing syndrome in adrenal incidentalomas: a 
prospective randomized study. Annals of Surgery. 2009 249 388-391.  
157. Sereg M, Szappanos A, Toke J, Karlinger K, Feldman K, Kaszper E, Varga I, Gláz E, Rácz K 
& Tóth M. Atherosclerotic risk factors and complications in patients with non-functioning adrenal 
adenomas treated with or without adrenalectomy: a long-term follow-up study. European Journal of 
Endocrinology 2009 160 647-655.  
158. Chiodini I, Morelli V, Salcuni AS, Eller-Vainicher C, Torlontano M, Coletti F, Iorio L, 
Cuttitta A, Ambrosio A, Vicentini L, Pellegrini F, Copetti M, Beck-Peccoz P, Arosio M, Ambrosi 
B, Trischitta V, Scillitani A. Beneficial metabolic effects of prompt surgical treatment in patients 
with an adrenal incidentaloma causing biochemical hypercortisolism. Journal of Clinical 
Endocrinology and Metabolism 2010 95 2736-45. 
159.Lal G & Duh QY. Laparoscopic adrenalectomy--indications and technique. Surgical Oncology 
2003 12 105-123. 
160. Murphy MM, Witkowski ER, Ng SC, McDade TP, Hill JS, Larkin AC, Whalen GF, Litwin 
DE & Tseng JF Trends in adrenalectomy: a recent national review. Surgical Endoscopy 2010 24 
2518-26.  
161. Tessier DJ, Iglesias R, Chapman WC, Kercher K, Matthews BD, Gorden DL & Brunt LM. 
Previously unreported high-grade complications of adrenalectomy. Surgical Endoscopy 2009 23 97-
102.  
162. Nieman LJ. Approach to the patient with an adrenal incidentaloma. Journal of Clinical 
Endocrinology and Metabolism 2010 95 4106-13. 
163. Terzolo M, Reimondo G & Angeli A. Definition of an optimal strategy to evaluate and follow-
up adrenal incidentalomas: time for further research. European Journal of Endocrinology 2009 161 
529-532. 
 
 
 
 
 
 
 
 
 
 
 
 
 
